
Refinitiv Eikon
View the recommended PC requirements for Refinitiv Eikon. Ensure your computer and network meet the requirements to install and run Refinitiv Eikon. Compare features with the desktop …
Eikon Therapeutics
4 days ago · Eikon has a growing therapeutic pipeline with the ability to deliver new medicines to address serious illnesses. At Eikon we know better insights will lead to better medicines.
Eikon Withdrawal and Transition to Workspace | Data Analytics
As part of our ongoing evolution, Eikon was withdrawn from LSEG’s product line on 30th June 2025. You can now supercharge your impact with our flagship data and analytics workflow …
Eikon raises $351M in one of the year’s largest biotech venture …
Feb 26, 2025 · Eikon was formed around a Nobel Prize-winning technology that helps scientists look at how proteins move inside of cells. The company debuted publicly in 2021 with Roger …
Eikon remains in megaround mode with $350M series D
Feb 26, 2025 · California-based Eikon emerged publicly in 2021 with a stated goal to apply live-cell super-resolution microscopy to drug discovery.
Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma …
Feb 26, 2025 · Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the …
Eikon pulls in $351M as lead drug begins Phase III journey
Feb 26, 2025 · Founded back in 2019, Eikon has since raised over $1.1 billion as it looks to build a pipeline leveraging Nobel Prize-winning super-resolution microscopy to visualise and …
News – Eikon Therapeutics
Apr 29, 2025 · Advancing breakthrough therapeutics through the purposeful integration of engineering and science.
Biotech Eikon Therapeutics Raises $350 Million
Feb 28, 2025 · Founded in 2019, Eikon Therapeutics specializes in live-cell resolution microscopy for drug discovery. This article is part of a series from Healthcare Insights on 2025 Trends in …
Eikon strikes it rich again, securing $351M to fund cancer trials …
Feb 26, 2025 · Eikon’s other top asset, EIK1003, is a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate or pancreatic cancers. …